CDAK Codiak BioSciences Inc.

FDA Catalyst Company
2.99
-0.2  -6%
Previous Close 3.19
Open 3.21
52 Week Low 2.5
52 Week High 27.09
Market Cap $67,256,662
Shares 22,493,867
Float 12,628,033
Enterprise Value $77,683,435
Volume 48,895
Av. Daily Volume 132,978
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Wedbush Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/22/2022
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/11/2022
Wedbush Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/09/2020
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/09/2020

Latest News

  1. CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data on the Company's engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene therapy. The data, which are being presented today at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), demonstrate that exosome engineering generates significant increases in AAV yield compared to unmodified exosomes, while retaining the functionality to transduce cells with AAV and resist neutralizing antibodies…

    View Full Article
  2. – Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –

    – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 –

    – Data from preclinical engEx-AAV™ program to be presented at ASGCT 2022 showing potential applications for engineered exosomes in gene delivery –

    CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported first quarter 2022 financial results and operational progress.

    "We are making exciting progress with our clinical and preclinical programs, which continue to generate further…

    View Full Article
  3. CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO.

    "We have been fortunate to work with David since late last year in an advisory capacity and are delighted to welcome…

    View Full Article
  4. – Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo

    CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced new preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family. The data, which are being presented today at the World Vaccine Congress 2022 in Washington, D.C., demonstrate the potential for a novel engineered exosome-based vaccine candidate derived from Codiak's exoVACC™…

    View Full Article
  5. – New preclinical data presented at AACR Annual Meeting 2022 –

    – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations –

    – Precision medicine approach enables potent single-agent activity in models of widely disseminated tumors –

    CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data on the Company's engineered exosome precision medicine candidate, exoASO-C/EBPβ. The data, which will be presented at the American Association for Cancer Research (AACR…

    View Full Article
View All Codiak BioSciences Inc. News